Does Interleukin-6 Bridge SARS-CoV-2 With Virus-Associated Cancers?
To date SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), a member of the Coronaviridae family, has infected more than 40 million people worldwide. A second wave of SARS-CoV-2 infection is aggressively surging. The clinical worsening of SARSCoV-2 infection appears to be strictly associat...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Innovative Healthcare Institute
2021-05-01
|
| Series: | Journal of Immunotherapy and Precision Oncology |
| Subjects: | |
| Online Access: | https://jipo.org/doi/pdf/10.36401/JIPO-20-27 |
| _version_ | 1828072848924606464 |
|---|---|
| author | Aldo Venuti Sara Donzelli Paola Nisticò Giovanni Blandino Gennaro Ciliberto |
| author_facet | Aldo Venuti Sara Donzelli Paola Nisticò Giovanni Blandino Gennaro Ciliberto |
| author_sort | Aldo Venuti |
| collection | DOAJ |
| description | To date SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), a member of the Coronaviridae family, has infected more than 40 million people worldwide. A second wave of SARS-CoV-2 infection is aggressively surging. The clinical worsening of SARSCoV-2 infection appears to be strictly associated with comorbidities, which can be used to establish an intrinsic patient network whose molecular profile is pivotal for identifying and successfully treating populations at risk. Herein, we focus on the direct interaction between SARS-CoV-2 and virus-associated cancers, exploring the critical role of interleukin-6 (IL-6) as a mediator of this complex cross talk. IL-6 production is enhanced in diverse viral infections ranging from human papilloma virus (HPV) to hepatitis B virus (HBV), human immunodeficiency virus (HIV), and SARS-CoV-2 infection. High systemic levels of IL-6 are associated with viral persistence and poor clinical outcomes in SARS-CoV-2–infected patients. Blockade of IL-6/IL-6R, using specific molecules, is under investigation in active clinical trials for the treatment of patients with SARS-CoV-2. Although the data are as yet inconclusive, they pave the way for selective targeting of crucial cytokine-activated aberrant signaling in SARS-CoV-2 infection. |
| first_indexed | 2024-04-11T01:18:32Z |
| format | Article |
| id | doaj.art-759f466651eb4cc1b63a15d6502d6ad1 |
| institution | Directory Open Access Journal |
| issn | 2666-2345 2590-017X |
| language | English |
| last_indexed | 2024-04-11T01:18:32Z |
| publishDate | 2021-05-01 |
| publisher | Innovative Healthcare Institute |
| record_format | Article |
| series | Journal of Immunotherapy and Precision Oncology |
| spelling | doaj.art-759f466651eb4cc1b63a15d6502d6ad12023-01-03T16:42:33ZengInnovative Healthcare InstituteJournal of Immunotherapy and Precision Oncology2666-23452590-017X2021-05-01798510.36401/JIPO-20-27i2590-017X-4-2-79Does Interleukin-6 Bridge SARS-CoV-2 With Virus-Associated Cancers?Aldo Venuti0Sara Donzelli1Paola Nisticò2Giovanni Blandino3Gennaro Ciliberto41 HPV-Unit, UOSD (Simple Departmental Operational Unit) Tumor Immunology and Immunotherapy, IRCCS (Scientific Institute for Research, Hospitalization and Healthcare) Regina Elena National Cancer Institute, Rome, Italy3 Oncogenomic and Epigenetic Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy2 UOSD Tumor Immunology and Immunotherapy, IRCCS Regina Elena National Cancer Institute, Rome, Italy3 Oncogenomic and Epigenetic Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy4 Scientific Direction, IRCSS Regina Elena National Cancer Institute, Rome, ItalyTo date SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), a member of the Coronaviridae family, has infected more than 40 million people worldwide. A second wave of SARS-CoV-2 infection is aggressively surging. The clinical worsening of SARSCoV-2 infection appears to be strictly associated with comorbidities, which can be used to establish an intrinsic patient network whose molecular profile is pivotal for identifying and successfully treating populations at risk. Herein, we focus on the direct interaction between SARS-CoV-2 and virus-associated cancers, exploring the critical role of interleukin-6 (IL-6) as a mediator of this complex cross talk. IL-6 production is enhanced in diverse viral infections ranging from human papilloma virus (HPV) to hepatitis B virus (HBV), human immunodeficiency virus (HIV), and SARS-CoV-2 infection. High systemic levels of IL-6 are associated with viral persistence and poor clinical outcomes in SARS-CoV-2–infected patients. Blockade of IL-6/IL-6R, using specific molecules, is under investigation in active clinical trials for the treatment of patients with SARS-CoV-2. Although the data are as yet inconclusive, they pave the way for selective targeting of crucial cytokine-activated aberrant signaling in SARS-CoV-2 infection.https://jipo.org/doi/pdf/10.36401/JIPO-20-27interleukin-6 (il-6)coronavirus-associated cancerssars-cov-2 |
| spellingShingle | Aldo Venuti Sara Donzelli Paola Nisticò Giovanni Blandino Gennaro Ciliberto Does Interleukin-6 Bridge SARS-CoV-2 With Virus-Associated Cancers? Journal of Immunotherapy and Precision Oncology interleukin-6 (il-6) coronavirus-associated cancers sars-cov-2 |
| title | Does Interleukin-6 Bridge SARS-CoV-2 With Virus-Associated Cancers? |
| title_full | Does Interleukin-6 Bridge SARS-CoV-2 With Virus-Associated Cancers? |
| title_fullStr | Does Interleukin-6 Bridge SARS-CoV-2 With Virus-Associated Cancers? |
| title_full_unstemmed | Does Interleukin-6 Bridge SARS-CoV-2 With Virus-Associated Cancers? |
| title_short | Does Interleukin-6 Bridge SARS-CoV-2 With Virus-Associated Cancers? |
| title_sort | does interleukin 6 bridge sars cov 2 with virus associated cancers |
| topic | interleukin-6 (il-6) coronavirus-associated cancers sars-cov-2 |
| url | https://jipo.org/doi/pdf/10.36401/JIPO-20-27 |
| work_keys_str_mv | AT aldovenuti doesinterleukin6bridgesarscov2withvirusassociatedcancers AT saradonzelli doesinterleukin6bridgesarscov2withvirusassociatedcancers AT paolanistico doesinterleukin6bridgesarscov2withvirusassociatedcancers AT giovanniblandino doesinterleukin6bridgesarscov2withvirusassociatedcancers AT gennarociliberto doesinterleukin6bridgesarscov2withvirusassociatedcancers |